JNJ Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Johnson & Johnson (NYSE: JNJ)
›
Johnson & Johnson (NYSE: JNJ) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 138,200 employees.
The shares were at 267.14 USD on 19 November 2026, up 37.9% over 52 weeks. Its 52-week range is 195.90 USD to 290.25 USD: the price is 8.0% below the high and 36.4% above the low.
At a market capitalisation of 643.09B USD, it trades at 40.5 times trailing earnings and 23.0 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.4, a premium of 59% for JNJ. It pays a dividend yielding 1.97% (it pays out 80% of its earnings), against a median of 2.55% among the dividend payers in that peer group.
Johnson & Johnson reports return on equity of 32.9%, an operating margin of 26.6% and revenue up 5.9% year over year.
Its debt exceeds its cash by 27.42B USD, a debt-to-equity ratio of 0.59. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 22 analysts cover the stock, with an average rating of Buy; their mean price target of 280.18 USD is 4.9% above the current price. The next earnings report is expected on 26 January 2027.